BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours

Sep 24, 2026

Uploaded by Rizky

Traditional radiotherapy and chemotherapy are widely used but often trigger adverse effects, driving the need for novel tumour treatments. BNIP3, a Bcl-2 family molecule with reported apoptosis-inducing activity, has been linked to cancer progression, yet its diagnostic and targeted-therapy potential remains unclear. The study shows that BNIP3 may influence tumour progression via an interaction with HDAC1, affecting multiple cancers and downstream signalling. Results support BNIP3 as a promising therapeutic and diagnostic target.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages6

Reading Time15 min

AccessFree to download

Abstract

Background

Findings

Interpretation

Study Rationale and Context

Rationale for targeting BNIP3

Yu etal. Molecular Cancer (2023) 22:143 Molecular Cancer [https://doi.org/10.1186/s12943-023-01808-9](https://doi.org/10.1186/s12943-023-01808-9) CORRESPONDENCE Open Access BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours Qin Yu 1†, Wenhao Fu2†, Yutang Fu2†, Wenjing Ye2†, Huiqiong Yan3,4†, Zecheng Yu2, Ruirui Li2, Yili Cai5, Yuxin Chen2, Lingyun Wang6, Xianqiao Wei2, Yangkun Chen2, Yuheng Zhang2, Huazhong Ying3,4,7, Furong Tang8,9*, Fangwei Dai3,4,7* and Wei Han3,4,7* Abstract Background Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) reportedly apoptosis-inducing effects in tumour cells and is associated with the progression and treatment of multiple tumours. Nevertheless, little is known about its potential role in tumour diagnosis and targeted therapy. Findings The results of the study demonstrated that the interaction of BNIP3 with HDAC1 may affect the progression of breast invasive cancer (BRCA), sarcoma (SARC), kidney renal clear cell carcinoma (KIRC), and low-grade glioma (LGG) . BNIP3 seemed to exert its effects in BRCA and SARC primarily through gene silencing and integrator complex, and in KIRC and LGG, mainly by affecting olfactory function, suggesting that targeted therapy can be developed based on the above signalling pathway and downstream molecules. Interpretation BNIP3 has emerged as a promising therapeutic and diagnostic target for BRCA, SARC, KIRC, and LGG, providing new insights into tumour molecular therapies in the clinic. Keywords BNIP3, Immune infiltration, Pan-cancer analysis, Prognostic biomarker, Diagnosis †Qin Yu, Wenhao Fu, Yutang Fu, Wenjing Ye and Huiqiong Yan contributed equally as the first author. *Correspondence: Furong Tang [furong.tang@hotmail.com](furong.tang@hotmail.com)[ ](furong.tang@hotmail.com)Fangwei Dai [fangweidai@163.com](fangweidai@163.com)[ ](fangweidai@163.com)Wei Han [hanwei3612@163.com](hanwei3612@163.com) 1School of Information Engineering, Hangzhou Medical College, Hangzhou, Zhejiang, China 2School of Medical Imaging, Hangzhou Medical College, Hangzhou, Zhejiang, China 3Center of Laboratory Animal, Hangzhou Medical College, Hangzhou 310013, Zhejiang, China 4Zhejiang Provincial Key Laboratory of Laboratory Animals and Safety Research, Hangzhou Medical College, Hangzhou 310013, Zhejiang, China 5School of Clinical Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China 6School of Medical Laboratory and Biological Engineering, Hangzhou Medical College, Hangzhou, Zhejiang, China 7Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College, Hangzhou 310013, Zhejiang, China 8The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital, Quzhou, Zhejiang, China 9Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this lic

FAQs

What is the main clinical problem addressed by this study?

Conventional radiotherapy and chemotherapy are associated with side effects, and there is limited understanding of BNIP3’s role in tumour diagnosis and targeted therapy.

How does BNIP3 relate to tumour progression according to the findings?

The study indicates that BNIP3 may affect progression through an interaction with HDAC1, impacting cancers including BRCA, SARC, KIRC, and LGG.

What conclusion does the interpretation support about BNIP3?

BNIP3 emerges as a promising therapeutic and diagnostic target across BRCA, SARC, KIRC, and LGG, offering new insights into molecular tumour therapies.

Sep 24, 2026

Uploaded by Rizky